Business Context and Reporting Period
This Form 8-K is filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on May 8, 2020. The registrant is an emerging growth company incorporated in California. The filing addresses operational disruptions caused by the COVID-19 pandemic and specific executive compensation arrangements related to workforce reductions.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the period. Specific financial details disclosed include:
- Executive Compensation: Approximately $471,000 approved for payment to former Chief Operating Officer Patrick Ryan, plus reimbursement for up to 12 months of COBRA coverage.
- Debt and Liquidity: The filing text does not provide clear values for current debt levels or liquidity positions, though it notes the uncertainty of securing additional financing.
Material Changes
- Workforce Reduction: The company implemented a second reduction in workforce as part of a previously announced winding down of operations. Patrick Ryan was separated effective April 17, 2020.
- Operational Disruption: Significant disruption occurred due to the COVID-19 pandemic, including office closures, material personnel reductions, and a shift to remote working arrangements.
- Reporting Delay: The company is unable to meet the filing deadline for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, due to delays in accounting procedures and independent auditor reviews.
Guidance, Outlook, and Risks
Regulatory Relief: The company is relying on an SEC order (Release No. 34-88318) to obtain a 45-day extension for filing its delayed 10-Q, estimating a new filing date of no later than June 29, 2020.
Outlook and Uncertainty: Management states it is unable to ascertain the overall impact of COVID-19 on its business. Future performance depends on uncertain factors including the duration of the outbreak, the ability to resume office operations, employee health, and the ability to secure joint ventures or additional financing.
Risks: If the pandemic evolves into a severe worldwide health crisis, it could have a material adverse effect on the company's business, results of operations, financial condition, cash flows, and common stock trading price.
Investor Verification Checklist
- Verify the actual filing date of the delayed Form 10-Q for the quarter ended March 31, 2020.
- Confirm the total extent of the workforce reduction and its impact on ongoing development of the Orion system.
- Monitor announcements regarding the company's ability to secure additional financing.
- Review the upcoming 10-Q for specific financial impacts of the pandemic and the winding down of operations.